Abliva Q3’20: Energizing Interactions
Redeye believes the key takeaway from the recent quarter is the positive momentum in clinical and regulatory development for lead candidate KL1333. Abliva has also initiated preliminary discussions with a US clinical trial regarding a possible collaboration for non-core asset NeuroSTAT.
Sign up for free to continue
Already a member?
Disclosures and disclaimers
Premium Plan required to unlock